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Schneeberger, Flege, Wolf, Merrill, Osterday,
Miller (left to right)doi:10.1016/j.jtcvs.2005.03.041Objective: Pulmonary vein isolation is curative in selected patients with atrial
fibrillation. The objective of this study was to assess the feasibility and safety
(midterm results) of video-assisted thoracoscopic epicardial pulmonary vein isola-
tion.
Methods: Twenty-seven patients (22 male patients) with atrial fibrillation (18
paroxysmal, 4 persistent, and 5 permanent; average age, 57 years) underwent
bilateral video-assisted thoracoscopic off-pump epicardial pulmonary vein isolation
and exclusion of the left atrial appendage. All patients had had unsuccessful drug
therapy or were intolerant to antiarrhythmic drug therapy or were intolerant to
warfarin. The approach included two 10-mm ports and one 5-cm working port
(non–rib spreading) bilaterally. Pulmonary vein isolation was achieved bilaterally
by using a bipolar radiofrequency device. The left atrial appendage was excised with
a surgical stapler.
Results: Bilateral pulmonary vein isolation and left atrial appendage excision was
performed successfully in all patients. There were no conversions to sternotomy or
thoracotomy. All patients were extubated in the operating room. Postoperative
complications in 3 patients were minor and resolved within 48 hours. One morbidly
obese patient had more serious complications related to comorbid conditions.
Average postoperative follow-up is approximately 6 months (173.6 days). Twenty-
three patients have been followed up for greater than 3 months, and 21 of these
patients are free of atrial fibrillation (91.3%). The results of magnetic resonance
angiography were normal (no pulmonary vein stenosis) in 12 of 12 patients
evaluated 3 to 6 months postoperatively.
Conclusions: Bilateral video-assisted thoracoscopic pulmonary vein isolation with
excision of the left atrial appendage is feasible and safe and offers a promising, new,
minimally invasive, beating-heart approach for curative surgical treatment of atrial
fibrillation.
Atrial fibrillation (AF) affects more than 2 million patients in the UnitedStates.1 AF is associated with increased mortality, increased risk of stroke,and exacerbation of heart failure.2-4 Antiarrhythmic medications have lim-
ited efficacy in maintaining sinus rhythm and might have serious adverse effects.5-7
The Cox maze III open surgical ablation has a success rate of more than 95%,
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although it has not been widely adopted because of the need
to perform extensive incisions and suturing of the atria,
resulting in lengthy procedure and crossclamp times.8 Al-
ternative approaches with bipolar radiofrequency (RF) ab-
lation to create transmural linear lesions have proved to be
effective and substantially decrease procedure and cardio-
pulmonary bypass times.9 Catheter-based ablation, which
attempts to eliminate or isolate pulmonary vein foci, has had
limited success, has a high incidence of recurrence, and is
associated with serious complications.10-15
A new, minimally invasive, video-assisted thoracoscopic
surgical (VATS) technique enables surgical treatment of AF
through an epicardial approach on a beating heart. The
procedure uses a bipolar RF ablation device, which can
Figure 1. Top, Dry bipolar RF clamp and RF generator s
of the dry bipolar clamp in place on the left atrial an
digital graph display of conductance of the tissue cla
lines on the epicardial surface after 8-second applicareliably create bilateral, transmural, linear lesions around
798 The Journal of Thoracic and Cardiovascular Surgery ● Septthe atrial cuff of the right and left pulmonary veins. This
effectively achieves electrical isolation of the pulmonary
veins without the need for cardiopulmonary bypass. Addi-
tionally, excision of the left atrial appendage (LAA), the
major source of thromboemboli associated with AF, is in-
corporated into this minimally invasive procedure.16
Methods
Patient Selection
Patients with symptomatic AF between 18 and 80 years of age were
selected on the basis of the following inclusion criteria: drug-refrac-
tory AF; inability to tolerate antiarrhythmic drugs or anticoagulation
therapy; left ventricular ejection fraction of 30% or greater; able to
provide written informed consent; life expectancy of at least 2 years;
(Atricure, Inc). Bottom left, Right thoracoscopic view
medial to the right pulmonary veins. Inset, Objective
between the devices. Bottom right, Visible ablation
.ystem
trum,
mped
tionsand able to attend scheduled follow-up visits. All patients consented
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ETto minimally invasive or open surgical treatment of their AF. The
study protocol was approved by the Institutional Review Board of the
University of Cincinnati College of Medicine.
Procedural Technique
A unique VATS procedure was developed to electrically isolate
the pulmonary veins bilaterally. A bipolar RF clamp and RF
generator system (Isolator, Atricure Inc) is used to achieve linear,
transmural ablation lesions (Figure 1, A). RF energy is delivered
between 2 gold-plated electrodes (1 mm wide  5 cm long)
embedded in the jaws of the clamp. The temperature of the tissue
1.5 mm from the electrode (within the clamped section) is dis-
played on the generator. A digital graph, located on the front panel
of the generator, displays the conductance of the tissue clamped
between the device jaws (Figure 1, B). When the conductance of
the tissue decreases to less than 0.0025 siemens, typically after 8
seconds, an audible signal is automatically generated to indicate
that the lesion is transmural. Ablation lines are visible on the
epicardial surface (Figure 1, C).
The procedure is conducted after achievement of general an-
esthesia administered with a double-lumen endotracheal tube.
Transesophageal echocardiography is performed in the operating
room to verify the absence of a left atrial thrombus before the start
of the procedure and adequacy of LAA excision at the end of the
procedure.
The right pulmonary veins are accessed first. The patient is
positioned with the left side down and the right arm abducted
above the head. The right lung is deflated, and a 10-mm trocar is
introduced in the sixth intercostal space in the anterior axillary
line. A 10-mm 30° thoracoscope is introduced through this port.
Insufflation is delivered at approximately 8 mm Hg to assist in
resorptive atelectasis. A 6-cm access port in the third intercostal
space just anterior to the anterior axillary line provides direct
visualization. The pleural space is entered, and a soft tissue retrac-
tor (CardioVations, Ethicon, Inc, Somerville, NJ) is placed without
spreading the ribs.
Blunt dissection of the right pulmonary veins is accomplished
under thoracoscopic guidance through the access port and lower
Figure 2. Lighted articulating dissector used to bluntly surround
the pulmonary veins (Wolf dissector).port site. First, the pericardium is incised from the superior vena
The Journal of Thoracicava to the inferior vena cava 3 cm anterior and parallel to the
phrenic nerve. Stay sutures in the posterior pericardial edge are
brought through the skin and anchored. Blunt dissection is used to
enter the oblique sinus behind the heart. An articulated lighted
dissector (AtriCure, Inc, Cincinnati, Ohio; Figure 2) is then intro-
duced into the chest through a port and passed into the oblique
sinus beneath the right inferior pulmonary veins. While the supe-
rior vena cava is distracted medially, dissection around the pul-
monary veins is completed with the lighted dissector.
The dissector is exchanged for an 18F red rubber catheter to
secure the path beneath the right pulmonary veins. The bipolar
clamp, with its lower jaw placed in the end of the red rubber
catheter, is introduced through the port incision. The red rubber
catheter is then used to guide the lower jaw of the clamp behind the
left atrial cuff adjacent to the right pulmonary veins as the upper
jaw passes in front of the veins. The red rubber catheter is then
removed. Correct positioning of the clamp on the atrium and not
on the pulmonary vein is verified by means of direct inspection of
the device after closing the jaws of the clamp (Figure 1, B). Once
the position of the jaws has been confirmed, bipolar RF energy is
applied to electrically isolate the pulmonary veins; 2 or more
overlapping lesions are created to ensure isolation. A 20F chest
tube or Blake silicone drain (Ethicon) is placed, the right lung is
reinflated, and the port sites are closed.
No heparin is used during the procedure because the clamp is
only in place for a maximum of 20 seconds. In addition, in
multiple laboratory studies in animals, no char or thrombus has
been observed on the endocardial surface of the ablation line.
The patient is repositioned with the right side down and the left
arm above the head. The technique is repeated on the left side with
the addition of division of the ligament of Marshall. As on the right
side, a red rubber catheter is placed beneath the left pulmonary
veins and is used to guide the bipolar clamp into place to ablate the
left atrial cuff adjacent to the left pulmonary veins (Figure 3).
The LAA is then excised by stapling it with an EZ 45 stapler
(Ethicon Endosurgery), which is introduced through one of the
Figure 3. Left thoracoscopic view of the dry bipolar clamp in
place on the left atrial antrum, medial to the left pulmonary veins.inferior port sites. The LAA exclusion is verified on transesopha-
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If the patients are not in sinus rhythm by the end of the procedure,
they are positioned supine and given a synchronized direct-current
shock to establish sinus rhythm. Extubation is routinely performed
in the operating room.
Data Analysis
Data were tabulated with an electronic database system (Kika, Inc,
Boston, Mass), and standard descriptive statistics were applied.
Results
From August 19, 2003, to August 13, 2004, the VATS
procedure described above has been performed in 29 pa-
tients with primary AF. Data on 27 of 29 patients treated are
presented in this report. One patient could not be reached for
enrollment, and the other patient was not entered because of
an ongoing drug addiction. Complete follow-up (100%) was
obtained on the remaining 27 patients from office visits,
medical records, telephone calls to the patients, and records
from cardiology visits.
Patient age ranged from 23 to 79 years (mean, 57.2
years), and the mean follow-up time for the 27-patient
cohort presented herein is currently (as of October 20, 2004)
173.6  88.2 days (range, 67-421 days). Patient character-
istics and underlying diseases are detailed in Table 1. Atrial
size was not specifically documented but was less than 6 cm
in all but 1 patient (who weighed 410 pounds). Preopera-
tively, 18 patients had paroxysmal AF, 4 patients had per-
sistent AF, and 5 patients had permanent AF. The duration
of preoperative AF ranged from 1 to 34 years (average, 7.5
years). Twenty-five patients were unresponsive to or did not
TABLE 1. Patient characteristics
Characteristic Results
Age (y) 57.2  14.9 (range, 23-79)
Sex 81.5% male (22/27)
Prior cardiac surgery 3.7% (1/27)
CAD 3.7% (1/27)
Mitral valve disease 3.7% (1/27)
Congestive heart failure 14.8% (4/27)
Cardiomyopathy 7.4% (2/27)
Prior stroke–TIA 14.8% (4/27)
Previous MI 3.7% (1/27)
Prior catheter ablations 7.4% (2/27)
Preoperative pacemaker 7.4% (2/27)
Preoperative cardioversion 55.6% (15/27)
Preoperative AADs
None 22.2% (6/27)
1 74.1% (20/27)
2 3.7% (1/27)
CAD, Coronary artery disease; TIA, transient ischemic attack; MI, myocar-
dial infarction; AADs, antiarrhythmic drugs.tolerate antiarrhythmic drugs (AADs). The remaining 2
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tions (bleeding) associated with warfarin therapy.
The technique was successfully completed in all patients,
with no conversions to sternotomy or thoracotomy. No
patients received blood products intraoperatively or during
the hospitalization, and all patients were extubated in the
operating room. The average procedure time was recorded
for 13 patients and ranged from 93 to 299 minutes. The
majority of patients were discharged within 3 days. Patient
outcomes are summarized in Table 2.
There has been no mortality in this population. No
patients required pacemaker insertion. Four patients had
complications; 3 were minor and quickly resolved. These
included a right pneumothorax (which resolved without
treatment), a right forearm phlebitis, and one case of
suspected pericarditis that resolved after oral steroid
administration.
More significant postoperative complications occurred in
a morbidly obese patient (410 lbs) with a 2-year history of
persistent AF, hypertension, and angina. The patient’s body
habitus made the procedure more difficult (approximately
doubling the procedure time), but there were no periopera-
tive complications. The patient was readmitted 3 weeks
after surgical intervention because of dyspnea and possible
AF. He was treated with antiarrhythmic medication and
electrical cardioversion. The patient was anemic, with an
increased international normalized ratio requiring transfu-
sions with packed red blood cells and fresh frozen plasma.
He was discharged home after 9 days in stable condition,
although he was readmitted 3.5 months postoperatively with
exacerbation of congestive heart failure and atrial flutter. He
responded to medical management, including the initiation
of amiodarone. He has since undergone an electrophysi-
ologic study with right flutter line and is now in normal
sinus rhythm.
Twenty-three of the 27 patients have more than 3 months
of postoperative data. Twenty-one (91.3%) of these 23
patients are free of AF, as confirmed on 12-lead electrocar-
TABLE 2. Patient outcomes
Outcome Results
Perioperative mortality 0%
Procedure time (min)* 178.4  55.9 (range, 93-299)
Hospital stay (d) 3.3  1.0 (range, 2-5)
Late mortality 0%
Reintervention 0%
Free of AF at 3 mo 91.3% (21/23)
Off AADs at 3 mo 65.2.9% (15/23)
AF, Atrial fibrillation; AADs, antiarrhythmic drugs. *Data recorded on 13
patients.diography (10 patients) or outpatient telemetry monitor (11
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tients had episodes of AF on outpatient telemetry monitor-
ing (5 and 6 months postoperatively). Preoperatively, one of
these patients had paroxysmal AF, and the other had per-
manent AF. The protocol included the use of AADs post-
operatively for approximately 3 months. Patients were then
to be weaned off AADs as tolerated. Fifteen of the 23
patients evaluated beyond 3 months have been successfully
weaned from AADs, and 6 were being weaned off AADs as
of their 3-month visit. The remaining 2 patients are con-
tinuing on AADs (1 receiving amiodarone and 1 receiving
sotalol). The results of magnetic resonance angiography
were normal (no pulmonary vein stenosis) in 12 patients
evaluated to date at greater than 3 months postoperatively.
Discussion
Optimal therapy for AF has been a challenge. Achieving
and maintaining sinus rhythm could result in fewer symp-
toms, lower stroke risk, eventual discontinuation of antico-
agulation (with its attendant bleeding risk), better exercise
tolerance, improved quality of life, and lower mortality.17
An extremely effective and nonpharmacologic approach has
been well established: surgical treatment of AF with the
maze procedure. Dr James Cox has reported success rates of
more than 95% in patients undergoing the Cox maze III
procedure.8 The complexity and morbidity associated with
the relatively prolonged cut-and-sew maze procedure have
limited its acceptance in the surgical community. These
open-chest techniques requiring cardiopulmonary bypass
are considered by many to be too invasive to be used for the
majority of patients with lone AF. Efforts to simplify this
procedure have used a variety of energy sources to create
lesions, including unipolar RF and microwave energy.18,19
The endocardial application of these unipolar energy
sources (as opposed to bipolar) does not easily enable
confirmation of transmurality, possibly producing an in-
complete and ineffective lesion.20 A lesion that is not con-
fined to the target tissue might result in injury to collateral
structures, particularly to the esophagus and pulmonary
veins.21-23 Gaynor and colleagues9 recently reported the use
of a bipolar RF ablation system (AtriCure Inc) to create
linear transmural lesions during cardiac surgery. The non-
irrigated bipolar clamp delivers energy between 2 electrodes
embedded in the jaws of the device, essentially eliminating
the risk of collateral damage. This technique has a success
rate of 91% at 6 months’ follow-up.
Efforts to develop a less invasive approach to AF abla-
tion were spurred by the identification of the importance of
the pulmonary veins in the pathogenesis of AF.10 To date,
*The CardioNet system is an ambulatory electrocardiographic monitor that
analyzes, stores, and transmits electrocardiographic data. The device is cleared
by the US Food and Drug Administration for use in patients with non–life-
threatening arrhythmias, such as AF (K012241).
The Journal of Thoracicatheter-based ablation has met with limited and variable
success, frequent failures, and occasional serious complica-
tions. As with endocardial surgical ablation, catheter-based
unipolar RF ablation is associated with potentially fatal
formation of fistulas between the left atrium and esopha-
gus.4 The use of saline-irrigated or cooled RF catheters, in
an effort to achieve deep transmural lesions, has a greater
risk of tissue eruption and cardiac perforation.24 Endoscop-
ically assisted techniques with unipolar and microwave
ablation devices are also under development.
The minimally invasive VATS approach to ablation of AF
we describe is safe and effective at intermediate follow-up.
This novel approach uses a bipolar nonirrigated RF clamp to
achieve pulmonary vein isolation. When the conductance
falls below a threshold value, a transmural lesion is
achieved.25 An additional benefit of bipolar ablation is that
current density is tightly confined to the tissue region be-
tween the electrodes. This limits lateral thermal spread of
the lesion, decreasing the possibility of collateral injury that
has been reported with unipolar surgical and catheter-based
RF ablations.
The minimally invasive surgical approach overcomes the
concerns related to the perceived invasive nature of the Cox
maze procedure. Our approach avoids the need for a ster-
notomy or rib-spreading thoracotomy. The epicardial ap-
proach enables this procedure to be performed on a beating
heart, avoiding the need for cardiopulmonary bypass. This
less invasive alternative might be viewed as a viable option
for younger patients with paroxysmal AF rather than a
procedure of last resort. The age of patients reported in this
series reflects this viewpoint.
Many of the limitations present with catheter ablation of
AF are addressed by using this approach. This technique
reliably and rapidly achieves continuous transmural lesions
encircling the pulmonary veins. Along with the previously
described technologic advantages of bipolar RF in creating
transmural lesions, direct visualization of the pulmonary
veins enhances the safety of this procedure. With this con-
trolled application of bipolar RF energy on the atrial cuff, no
patients had pulmonary vein stenosis. Catheter ablation has
a risk of stroke associated with thrombus that forms when
the tissue impedance increases, heating the blood pool. The
bipolar nonirrigated device is not associated with this risk
because the ablation line is confined within the jaws of the
device. This protects both surrounding structures, as well as
the blood pool.26 Finally, the ability to exclude the LAA,
which is not possible with catheter-based ablation, further
decreases the risk of thromboembolic complications in this
patient population.
There is concern that pulmonary vein isolation without
connecting lesions can lead to decreased efficacy11 and can
potentially lead to postablation atrial flutter. Concerns have
also been raised regarding the efficacy of pulmonary vein
c and Cardiovascular Surgery ● Volume 130, Number 3 801
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AF.27 Our approach results in wide isolation of the pulmonary
veins and antrum, resulting in isolation of a large left atrial
volume. Although the extent of left atrial ablation required to
achieve success in a given patient is uncertain and the overall
volume that should be isolated is debated, there is evidence that
more extensive ablation of the atrium increases success of the
procedure.28,29 Atrial tachyarrhythmias (including atrial flutter)
after ablation procedures are most commonly caused by in-
complete and nontransmural ablation lines.30,31 Bipolar abla-
tion reduces these risks by ensuring lesion transmurality. Only
one patient in this study had atrial flutter. Nine of the 27
patients treated had either persistent or permanent AF, and
success was achieved in all these patients. Further follow-up is
necessary to determine the long-term cure rate and to elucidate
the effect of AF type on success.
This minimally invasive technique is safe, effective, and
appears to be an attractive alternative to antiarrhythmic medi-
cal therapy, long-term anticoagulation, or catheter-based abla-
tion. We are now performing this procedure on patients with
prior cardiac surgery and previous catheter ablations. We have
also added intraoperative pacing and sensing to confirm bidi-
rectional block of the ablation lines. In addition, we attempt to
identify and map the ganglionic plexi, which are then ablated
to decrease autonomic innervation of the heart, which we
believe might enhance results. Continuing study evaluating the
long-term safety and efficacy of this approach is indicated.
References
1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial
fibrillation in adults: national implications for rhythm management for
rhythm management and stroke prevention: the Anticoagulation and
Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:
2370-5.
2. Lin HJ, Wolf PA, Benjamin EJ, Belanger AJ, D’Agostino RB. Newly
diagnosed atrial fibrillation and acute stroke: the Framingham Study.
Stroke. 1995;26:1527-30.
3. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB,
Levy D. Impact of atrial fibrillation on the risk of death: the Framing-
ham Heart Study. Circulation. 1998;98:946-52.
4. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA,
Stevenson LW. Atrial fibrillation is associated with an increased risk
for mortality and heart failure progression in patients with asymptom-
atic and symptomatic left ventricular systolic dysfunction: a retrospec-
tive analysis of the SOLVD trials. J Am Coll Cardiol. 1998;32:695-
703.
5. Crijns HJ, Van Gelder IC, Van Gilst WH, Hillege H, Gosselink AM,
Lie KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm
after electrical cardioversion for chronic atrial fibrillation or atrial
flutter. Am J Cardiol. 1991;68:335-41.
6. Falk R. Proarrhythmia in patients treated for atrial fibrillation or atrial
flutter. Ann Intern Med. 1992;117:141-50.
7. Flaker GC, Blackshear JL, McBride R, Kronman RA, Halperin JL,
Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial
fibrillation. The stroke prevention in atrial fibrillation investigators.
J Am Coll Cardiol. 1992;29:527-32.
8. Cox JL, Ad N, Palazzo T, et al. Current status of the maze procedure
for the treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg.
2000;12:15-9.
802 The Journal of Thoracic and Cardiovascular Surgery ● Sept9. Gaynor SL, Diodato MD, Prasad SM, et al. A prospective, single-
center clinical trial of a modified Cox maze procedure with bipolar
radiofrequency ablation. J Thorac Cardiovasc Surg. 2004;124:535-42.
10. Haissaguere M, Jais P, Shah DC, et al. Spontaneous initiation of atrial
fibrillation by ectopic beats originating in the pulmonary veins. N Engl
J Med. 1998;339:659-66.
11. Oral H, Scharf C, Chugh A, et al. Catheter ablation for paroxysmal
atrial fibrillation: segmental pulmonary vein ostial ablation versus left
atrial ablation. Circulation. 2003;108:2355-60.
12. Cappato R, Negroni S, Pecora D, et al. Prospective assessment of late
conduction recurrence across radiofrequency lesions producing elec-
trical disconnection at the pulmonary vein ostium in patients with atrial
fibrillation. Circulation. 2003;108:1599-604.
13. Saad EB, Rossillo A, Saad CP, et al. Pulmonary vein stenosis after
radiofrequency ablation of atrial fibrillation: functional characteriza-
tion, evolution, and influence of the ablation strategy. Circulation.
2003;108:3102-7.
14. Pappone C, Oral H, Santinelli V, et al. Atrio-esophageal fistula as a
complication of percutaneous transcatheter ablation of atrial fibrilla-
tion. Circulation. 2004;109:2724-6.
15. Scanavacca MI, D’Avila A, Parga J, Sosa E. Left atrial-esophageal
fistula following radiofrequency catheter ablation of atrial fibrillation.
J Cardiovasc Electrophysiol. 2004;15:960-2.
16. Halperin JL, Hart RG. Atrial fibrillation and stroke: new ideas, per-
sisting dilemmas. Stroke. 1988;19:937-41.
17. Friedman PA, Hammill SC. Atrial fibrillation therapies-rate or rhythm
control? Business Briefing: US Cardiol. 2004:115-8.
18. Damiano RJ. Alternative energy sources for atrial ablation: judging the
new technology. Ann Thorac Surg. 2003;75:329-30.
19. Knaut M, Tugtekin SM, Spitzer S, Gulielmos V. Combined atrial
fibrillation and mitral valve surgery using microwave technology.
Semin Thorac Cardiovasc Surg. 2002;14:226-31.
20. Ouyang F, Antz M, Ernset S, et al. Recovered pulmonary vein con-
duction as a dominant factor for recurrent atrial tachyarrhythmias after
complete circular isolation of the pulmonary veins. Circulation. 2005;
111:127-35.
21. Doll N, Borger MA, Fabricus A, et al. Esophageal perforation during
left atrial radiofrequency ablation: is the risk too high? J Thorac
Cardiovasc Surg. 2003;125:836-42.
22. Gillinov AM, Petterson G, Rice TW. Esophageal injury during radio-
frequency ablation for atrial fibrillation. J Thorac Cardiovasc Surg.
2001;122:1239-40.
23. Sonmez B, Demirsoy E, Yagan N, et al. A fatal complication due to
radiofrequency ablation for atrial fibrillation: atrial-esophageal fistula.
Ann Thorac Surg. 2003;76:281-3.
24. Cooper JM, Sapp JL, Tedrow U, et al. Ablation with internally
irrigated radiofrequency catheter: learning how to avoid steam pops.
Heart Rhythm. 2004;1:329-33.
25. Prasad SM, Maniar HS, Schuessler RB and Damiano RJ Jr. Chronic
transmural atrial ablation by using bipolar radiofrequency energy on
the beating heart. J Thorac Cardiovasc Surg. 2002;124:708-13.
26. Kok LC, Mangrum JM, Haines DE, Mounsey JP. Cerebrovascular
complications associated with pulmonary vein ablation. J Cardiovasc
Electrophysiol. 2002;13:768-9.
27. Oral H, Scharf C, Chugh A, et al. Catheter ablation for paroxysmal
atrial fibrillation: segmental pulmonary vein ostial ablation versus left
atrial ablation. Circulation. 2003;108:2355-60.
28. Marrouche NF, Dresing T, Cole C, et al. Circular mapping and
ablation of the pulmonary vein for treatment of atrial fibrillation:
impact of different catheter technologies. J Am Coll Cardiol. 2002;40:
464-74.
29. Pappone C, Santinelli V, Manguso F, et al. Pulmonary vein denerva-
tion enhances long-term benefit after circumferential ablation for par-
oxysmal atrial fibrillation. Circulation. 2004;109:327-34.
30. Gaita F, Riccardi R, Caponi D, et al. Linear cryoablation of the left
atrium versus pulmonary vein cryoisolation in patients with permanent
atrial fibrillation and valvular heart disease. Circulation. 2005;111:
136-42.
31. Kobza R, Hindricks G, Tanner H, et al. Late recurrent arrhythmias
after ablation of atrial fibrillation: incidence, mechanisms and treat-
ment. Heart Rhythm. 2004;1:676-83.
ember 2005
